Jerome Sarris

Jerome Sarris is the Chief Scientific Officer (CSO) of Psychae Therapeutics (Co-CEO 2022-24) and an Executive Co-Director of the associated Not-For-Profit Psychae Institute. Psychae Therapeutics is a biotechnology company seeded by Genesis and Tin Alley Ventures at Melbourne University. He was also appointed in the field of psychology to the position of Professor of Psychedelic Medicine at The Centre of Mental Health at Swinburne University of Technology He also holds Adjunct roles at NICM Health Research Institute at Western Sydney University, Australia, and at the Florey Institute of Neuroscience and Mental Health at the University of Melbourne, Australia.

Sarris' principal research interests pertain to the development and clinical study of psychedelic therapies and psychoactive plant-based medicines for mental disorders and other diseases. He is also interested in lifestyle medicine in anxiety and mood disorders, psychotropic plant medicines (such as kava), as well as the use of pharmacogenetics to guide psychiatric treatment. He is involved in prominent research projects investigating the therapeutic potential of psychedelic medicines. Provided by Wikipedia